# Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

> **NCT00078221** · PHASE3 · UNKNOWN · sponsor: **OccuLogix** · enrollment: 180 (—)

## Conditions studied

- Macular Degeneration

## Interventions

- **DEVICE:** Rheopheresis blood filtration

## Key facts

- **NCT ID:** NCT00078221
- **Lead sponsor:** OccuLogix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 180 (—)
- **Last updated:** 2008-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078221, "Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00078221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*